ProQR Therapeutics reported a second quarter net loss of 11.7 million euros, or 0.30 euros per share, compared with a net loss of 7.4 million euros, or 0.23 euros per share, in the same quarter of 2018, according to a press release.
Research and development costs totaled 9.5 million euros compared with 6 million euros a year ago. The increase was attributed to the initiation of clinical trials of sepofarsen for Leber’s congenital amaurosis 10 and QR421a for Usher syndrome type 2.
General and administrative costs increased from 2.6 million euros in 2018 to 2.9 million euros in 2019.
The company had cash and cash equivalents of 82.5 million euros as of June 30.